2005, NucleaRDB.
This data was extracted from Medline abstracts and full texts (when available) in an automated manner.
The table below describes the selected point mutation and provides links to other documents. The sentence(s) where the point mutation S112A was found are listed after the table.
The mutated residues are also indicated in the family sequence alignments and hyperlinked to the corresponding mutation pages.
| Point mutation: | S112A | |
| Domain: | N-term | |
| General numbering (NucleaRDB): | - | |
| Protein: | PPAT_HUMAN (PPARG,NR1C) | Swiss-Prot Cross-reference table Family page |
| Protein isoforms | 2 | |
| Other point mutations / same protein | List of mutations in PPAT_HUMAN | |
| Family alignments |
1C3 PPAR gamma 1C Peroxisome proliferator activated (PPAR) 1 Thyroid hormone like (TR,RAR,ROR,PPAR,VDR | |
| Other point mutations / same position |
Position 82 in 1C3 PPAR gamma family Position 76 in 1C Peroxisome proliferator activated (PPAR) family Position 26 in 1 Thyroid hormone like (TR,RAR,ROR,PPAR,VDR family | |
| Reference: | Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O, Kobayashi M Diabetes 2001 May;50(5):1083-92. | Medline |
| Other point mutations / same article | List | |
| Text source | HTML and PDF full texts | |
| Validation status | True positive |
Relevant sentences:
S112A
cmbi.kun.nl), 21-Apr-2005